TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Presence or absence of T2DM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in stress response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in incidence of adverse events of cannabinoids
Endpoint domain: Adverse events/effects
Primary endpoint: Rectus abdominis distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 8-week substance use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visualization of anatomical nerve structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Objective Function Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of CAB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of photoreceptor outer and inner segment loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ultrasound diaphragmatic trophism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ultrasound diaphragmatic contractility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ultrasound diaphragmatic excursion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Word association task performance immediately after NITEGON/sham
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Word association task performance at 7 days
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Word association task performance at 28 days
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Treatment-emergent adverse effects as assessed by Comprehensive Metabolic Profile
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment-emergent adverse effects as assessed by creatinine levels
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment-emergent adverse effects as assessed by liver function tests
Endpoint domain: Adverse events/effects
Primary endpoint: Balance of the autonomic nervous system upon waking
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: GVHD-free and relapse-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Misophonia Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in State-Trait Anxiety Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Whole-body protein synthesis rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Past year experience of any violence from a partner
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Acceptability of violence (personal belief)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tHalf
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dd-cfDNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with a new diagnosis of FH
Endpoint domain: Mortality/survival
Primary endpoint: Subjective Health Complaints Inventory
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of participants experiencing Grade 3 or Higher study drug-related toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Change in retinal thickness measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Writing Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive Effort Measured by Pupil Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Respiratory airway pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Fugl-Meyer Assessment (FMA) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of fractions with bladder volumes <200 ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in child mental health using the Strengths and Difficulties Questionnaire (SDQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in child's post-traumatic symptoms using the Revised Child Impact of Events Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in child mental health using the Revised Children's Anxiety and Depression Scale (RCADS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sensitivity of the electroretinogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Measurement of Lower Extremity Muscle Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The 6-minute walking test (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endoleak occurrence up to hospital discharge
Endpoint domain: Adverse events/effects
Primary endpoint: Endoleak occurrence to one-year post-surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Inhibitor Eradication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in ALP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activation of spinal circuits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Visual Analogue Scale of Pain Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD8+ TIL Tumor Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change from baseline in maximal mouth opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from baseline in shoulder joint range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: proportion of pedicle screws within 2 mm of cortical breach
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Deep core muscles thickness by USI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deep core muscles thickness by MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deep core muscles cross-sectional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lumbar proprioception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional performance-Timed Up-and-Go
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional performance-Five-Times Sit-to-Stand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Satisfaction with Facial Appearance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Achievement of pain palliation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in body mass index (BMI) percentile - child
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in body mass index (BMI) percentile - adult
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in blood pressure - child
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in blood pressure - adult
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Hemoglobin A1c - child
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Hemoglobin A1c - adult
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Adverse Events up to 4 hours post Cell Infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Adverse Events up to 4 weeks of T-cell Transfer
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of newly occurring acute rejection of kidney allograft until Week 12 after T-cell transfer
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of de novo antibodies against kidney allograft donor (dnDSA) until Week 52 after T-cell transfer
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of newly occurring acute GVHD grade ≥1 or aggravation of pre-existing acute GVHD until Week 12 after T-cell transfer
Endpoint domain: Adverse events/effects
Primary endpoint: Health-related quality of life (EuroQol-5D)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in sick leave
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in self-reported productivity
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Incidence of hypotension after induction of general anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Post-operative knee outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peptide C evolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: % recovery of thigh muscle volume (TMV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: PPT of upper fiber of trapezius muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in the overall taxonomic profiles of the salivary bacterial communities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in the relative abundance of individual bacterial taxa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in the salivary cytokines levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Muscular activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Algometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Respiratory Muscle Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Physical Function Test (PFIT) battery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Remission of disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Total Combined Score (TCS) During the Birch Pollen Season
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Detection of hyperdiploidy in Multiple Myeloma patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of anal-cancers-associated complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean FEV1 Percent Predicted Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean Primary Ciliary Dyskinesia-Quality of Life Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean PCD-Respiratory Symptom Diary Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Numbers of participants with Adverse Events (AEs) or Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Numbers of participants with clinical laboratory tests abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numbers of participants with vital sign abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: learning effectiveness assessment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: user experience feedback
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tooth color assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interproximal Modified Lobene Stain Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fibrinogen to albumin ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Concentration of lactate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of children prescribed antibiotic treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of children with clinical failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Seated Office Systolic Blood Pressure (SBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Elderly health promotion scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Subjective assessment of lens wear experience
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Engagement in biosensor wearing
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Adherence to the aktivplan digital intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Usability of the aktivplan digital intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: User experience of the aktivplan digital intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Effectiveness in reaching MSM for HIV testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Usability and acceptability of user interfaces
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety profile of COM503
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in worst-itch numeric rating scale (WI-NRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence Rate and Severity of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in composite score of Silent Spaces, Xrs and SOPI (mechanical ventilation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in composite score of Silent Spaces and SOPI (non-invasive respiratory support)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Silent Spaces (areas of atelectasis as well as overdistension)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in respiratory reactance (Xrs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Saturation oxygenation pressure index (SOPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of participants with alleviated rectal bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Measurement of anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in orthostatic tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in peak aerobic power (VO2max test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in the Vineland II Adaptive Behaviour Scale (VABS-II) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Occurrences of Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in HAMD-17 score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: RPL8 status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall efficacy response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of treatment-emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Gut Microbial Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time of no response to nerve stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change of the Average Daily Pain Score (ADPS)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Mean change in LGR5+ cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Methacholine challenge dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in pre-bronchodilator FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Contrast to noise ratio of obstetric ultrasound image
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention and Attrition Rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of subjects with headache pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects with absence of the Most Bothersome Symptom
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Caregiver Quality of Life-Index (CQLI-R) scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of participants with vIGA-AD of 0 or 1 and a reduction from baseline of ≥2 points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants reaching 75% reduction in EASI score (EASI75)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in weekly average of daily SD-NRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Graded Cycling Test with Talk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Energy Intake from breakfast meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of C reactive protein (CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: extended safety of TDM 300mg daily
Endpoint domain: Adverse events/effects
Primary endpoint: Cardiometabolic Risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Appropriateness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sensitivity of FES PET/MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: biochemically validated abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Type, frequency, severity and outcome of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Investigator-assessed objective response rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended dose for the phase II study (RP2D)
Endpoint domain: Resource use
Primary endpoint: Change of NIPS (Neonatal Infant Pain Scale) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of SpO2 (Oxygen Concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change of HR (Heart Rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of RR (Respiratory Rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Procedural memory formation and consolidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Utility of ESD for treatment of gastrointestinal lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Weight loss > 3%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of Cardiac MRI methods
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quality bowel preparation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Evolution of brain lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Nalbuphine consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Dry Eye and eye strain knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of the five-times sit-to-stand test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in salivary IL-1ß levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in salivary TNF-α levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in salivary IL-4 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in subgingival total bacterial load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Autoregulation index (ARI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone myoregulation reflex latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bereitschafts (Readiness) Potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rapid Entire Body Assessment (REBA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients requiring ICD implantation for prevention of sudden cardiac death
Endpoint domain: Mortality/survival